Total Payments
$402,834
2024 Payments
$47,901
Companies
18
Transactions
285
Payment Breakdown by Category
Consulting$199,594 (49.5%)
Research$121,705 (30.2%)
Other$56,576 (14.0%)
Travel$21,198 (5.3%)
Food & Beverage$3,562 (0.9%)
Education$185.89 (0.0%)
Gifts$11.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $199,594 | 52 | 49.5% |
| Unspecified | $121,705 | 107 | 30.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,456 | 32 | 13.3% |
| Travel and Lodging | $21,198 | 42 | 5.3% |
| Food and Beverage | $3,562 | 43 | 0.9% |
| Honoraria | $3,120 | 1 | 0.8% |
| Education | $185.89 | 4 | 0.0% |
| Gift | $11.96 | 4 | 0.0% |
Payments by Type
General
$281,129
178 transactions
Research
$121,705
107 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BIOVERATIV THERAPEUTICS INC. | $100,126 | 86 | $0 (2021) |
| Genentech USA, Inc. | $65,831 | 52 | $0 (2024) |
| Kedrion S.p.A. | $50,085 | 4 | $0 (2023) |
| F. Hoffmann-La Roche AG | $37,515 | 31 | $0 (2024) |
| Novo Nordisk Health Care AG | $37,078 | 14 | $0 (2024) |
| Novo Nordisk Inc | $36,101 | 30 | $0 (2024) |
| GENZYME CORPORATION | $33,869 | 18 | $0 (2024) |
| Shire North American Group Inc | $8,993 | 19 | $0 (2017) |
| PFIZER INC. | $8,280 | 9 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $7,693 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,901 | 22 | Novo Nordisk Health Care AG ($19,758) |
| 2023 | $62,427 | 25 | Kedrion S.p.A. ($26,180) |
| 2022 | $37,750 | 14 | Kedrion S.p.A. ($23,905) |
| 2021 | $22,063 | 22 | F. Hoffmann-La Roche AG ($5,846) |
| 2020 | $36,917 | 23 | F. Hoffmann-La Roche AG ($16,284) |
| 2019 | $58,334 | 53 | Genentech USA, Inc. ($24,984) |
| 2018 | $116,396 | 89 | BIOVERATIV THERAPEUTICS INC. ($81,934) |
| 2017 | $21,046 | 37 | Genentech USA, Inc. ($10,332) |
All Payment Transactions
285 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $2,262.43 | Research |
| Study: Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database • Category: Hematology | ||||||
| 12/06/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $128.91 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $526.16 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $281.37 | General |
| 11/01/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $247.77 | General |
| 10/18/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ | — | In-kind items and services | $330.00 | Research |
| Study: BENEFIX CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 10/18/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological), ALPROLIX | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Hematology | ||||||
| 10/02/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $807.00 | General |
| 06/25/2024 | GENZYME CORPORATION | ALPROLIX (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B • Category: Hematology | ||||||
| 06/24/2024 | PFIZER INC. | XYNTHA (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: MOROCTOCOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 06/06/2024 | Novo Nordisk Health Care AG | — | Consulting Fee | Cash or cash equivalent | $11,500.00 | General |
| 06/06/2024 | Novo Nordisk Health Care AG | — | Travel and Lodging | In-kind items and services | $7,284.95 | General |
| 06/06/2024 | Novo Nordisk Health Care AG | — | Travel and Lodging | In-kind items and services | $671.89 | General |
| 06/06/2024 | Novo Nordisk Health Care AG | — | Food and Beverage | In-kind items and services | $301.63 | General |
| 04/22/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $5.55 | General |
| 04/03/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,232.98 | General |
| 02/18/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $4,250.00 | General |
| 01/17/2024 | PFIZER INC. | XYNTHA (Biological), BENEFIX | — | In-kind items and services | $330.00 | Research |
| Study: PF05230907 PF05280602 GIROCTOCOGENE FITELPARVOVEC FIDANACOGENE ELAPARVOVEC MARSTACIMAB MOROCTOCOG ALFA MULTI PRODUCT NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 12/13/2023 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PF05280602 CLINICAL PUBLICATION PROGRAM | ||||||
| 12/08/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $16,687.00 | General |
| 12/08/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $154.55 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | BIOVERATIV THERAPEUTICS INC. | $56,650 | 43 |
| Natural History Study of Factor IX Treatment and Complications (B-Natural) | BIOVERATIV THERAPEUTICS INC. | $15,653 | 8 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $5,500 | 1 |
| Six-month real-world experience of emicizumab prophylaxis in people with hemophilia A Data from the Indiana Hemophilia and Thrombosis Center | F. Hoffmann-La Roche AG | $4,845 | 1 |
| Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis Realworld experience from a large comprehensive treatment centre in the US | F. Hoffmann-La Roche AG | $4,641 | 1 |
| FIDANACOGENE ELAPARVOVEC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| MOROCTOCOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,150 | 4 |
| Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment | BIOVERATIV THERAPEUTICS INC. | $2,700 | 4 |
| Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database | F. Hoffmann-La Roche AG | $2,262 | 1 |
| A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV00 | BIOVERATIV THERAPEUTICS INC. | $2,002 | 5 |
| An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B | GENZYME CORPORATION | $2,000 | 3 |
| Clinical Characteristics and Outcomes of Hemophilia B Patients Managed with ALPROLIX in Routine Clinical Practice | BIOVERATIV THERAPEUTICS INC. | $1,795 | 1 |
| Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B | BIOVERATIV THERAPEUTICS INC. | $1,511 | 1 |
| CHARACTERIZING MILD AND MODERATE HEMOPHILIA A PATIENTS IN THE REAL WORLD A PATIENT-CENTRIC APPROACH | F. Hoffmann-La Roche AG | $1,309 | 2 |
| An Open-label, Multi-center Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects with Severe Hemophilia B | GENZYME CORPORATION | $1,250 | 1 |
| A NOVEL METHODOLOGY FOR BUILDING LONGITUDINAL, PATIENT-CENTRIC REAL WORLD DATASETS IN HEMOPHILIA A | F. Hoffmann-La Roche AG | $1,116 | 2 |
| Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale | BIOVERATIV THERAPEUTICS INC. | $1,070 | 2 |
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A | GENZYME CORPORATION | $1,000 | 3 |
| PF05280602 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A (A-LONG) | BIOVERATIV THERAPEUTICS INC. | $893.33 | 1 |
| B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment | BIOVERATIV THERAPEUTICS INC. | $831.60 | 3 |
| DEVELOPMENT AND VALIDATION OF THE COMPREHENSIVE ASSESSMENT TOOL FOR CHALLENGES IN HEMOPHILIA CATCH A PRO INSTRUMENT TO ASSESS THE EXPERIENCE OF PATIENTS WITH HEMOPHILIA | F. Hoffmann-La Roche AG | $781.90 | 1 |
| Long-term efficacy and safety of prophylactic treatment with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with severe or moderate haemophilia B: final longitudinal analysis of B-LONG/ | BIOVERATIV THERAPEUTICS INC. | $730.91 | 1 |
| Early Patient Experiences with Emicizumab in the United States a Qualitative Study | F. Hoffmann-La Roche AG | $711.66 | 2 |
| Retrospective chart review of hemophilia A patients with inhibitors treated with rFVIIIFc for ITI | BIOVERATIV THERAPEUTICS INC. | $648.26 | 2 |
| Final Results of PUPs B-LONG Study: Evaluating Safety and Efficacy of rFIXFc in Previously Untreated Patients With Hemophilia B | BIOVERATIV THERAPEUTICS INC. | $618.46 | 1 |
| Inhibitors in Previously Untreated Patients With Severe Haemophilia A Treated With rFVIIIFc: PUPs A-LONG Study, Interim data | BIOVERATIV THERAPEUTICS INC. | $600.00 | 1 |
| Long-term safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) in previously treated subjects of all ages with haemophilia B: Final results from the B-YOND extension trial | BIOVERATIV THERAPEUTICS INC. | $488.40 | 1 |
| A MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS. | F. Hoffmann-La Roche AG | $448.41 | 1 |
| Improved hemostasis and joint health over time in a subset of patients who did not reach optimal hemostatic control in the first year of rFVIIIFc therapy | BIOVERATIV THERAPEUTICS INC. | $353.33 | 1 |
| BENEFIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| NONACOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| PF05230907 PF05280602 GIROCTOCOGENE FITELPARVOVEC FIDANACOGENE ELAPARVOVEC MARSTACIMAB MOROCTOCOG ALFA MULTI PRODUCT NONACOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| CLAIMS-BASED ALGORITHMS TO IDENTIFY PERSONS WITH SEVERE HEMOPHILIA A | F. Hoffmann-La Roche AG | $300.00 | 1 |
| BIVV001: The First Investigational Factor VIII (FVIII) Therapy to Break Through the Von Willebrand Factor (VWF) Ceiling, with Potential for More Optimal, Extended Protection in Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $265.00 | 1 |
| Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG) | SANOFI-AVENTIS U.S. LLC | $244.62 | 1 |
| BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $205.70 | 1 |
About Dr. Amy Shapiro, MD
Dr. Amy Shapiro, MD is a Pediatric Hematology-Oncology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942380274.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Shapiro, MD has received a total of $402,834 in payments from pharmaceutical and medical device companies, with $47,901 received in 2024. These payments were reported across 285 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($199,594).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Indianapolis, IN
- Active Since 10/17/2006
- Last Updated 09/08/2021
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1942380274
Products in Payments
- ELOCTATE (Drug) $67,903
- HEMLIBRA (Biological) $63,794
- Non-Covered Product (Drug) $19,726
- NO PRODUCT DISCUSSED (Drug) $15,660
- Hemlibra (Biological) $12,460
- ALPROLIX (Biological) $5,726
- ALPROLIX (Drug) $3,546
- NovoSeven (Biological) $3,200
- ELOCTATE (Biological) $3,121
- Idelvion (Biological) $3,120
- SevenFact (Biological) $3,012
- BIVV001 (Drug) $2,871
- Gammaplex (Drug) $2,250
- XYNTHA (Biological) $1,270
- Rebinyn (Biological) $1,200
- NovoSeven RT (Drug) $904.19
- BENEFIX (Biological) $660.00
- HEMGENIX (Biological) $178.89
- BMN 270 (Biological) $31.11
- ALTUVIIIO (Biological) $16.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Indianapolis
Dr. Bassem Razzouk, Md, MD
Pediatric Hematology-Oncology — Payments: $46,110
Pediatric Hematology-Oncology $46,110
W. Scott Goebel, Md, MD
Pediatric Hematology-Oncology — Payments: $42,209
Pediatric Hematology-Oncology $42,209
Melissa Bear, M.d, M.D
Pediatric Hematology-Oncology — Payments: $26,181
Pediatric Hematology-Oncology $26,181
Dr. Kerry Hege, M.d, M.D
Pediatric Hematology-Oncology — Payments: $19,106
Pediatric Hematology-Oncology $19,106
April Rahrig
Pediatric Hematology-Oncology — Payments: $8,652
Pediatric Hematology-Oncology $8,652
Dr. Steven Rhodes, M.d., Ph.d, M.D., PH.D
Pediatric Hematology-Oncology — Payments: $7,263
Pediatric Hematology-Oncology $7,263